QIAGEN Digital Insights and ATCC launch cell line database to enable faster and more reliable biopharma preclinical research results
November 2, 2022: [Press release]
Further Information
- ATCC Cell Line Land allows use of cell cultures without lengthy and costly gene sequencing
- Database provides information about actual lots of cell lines stored in ATCC’s biorepository
- QDI is committed to providing customers the most comprehensive manually curated content
Redwood City, California, and Hilden, Germany, November 2, 2022 — QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, today announced the launch of their new cell line database developed through its partnership with ATCC, the leading biological materials organization, developer and supplier of authenticated cell lines. This database offers manually curated sequencing data for standardized, authenticated and reproducible cell lines. It will allow biopharma researchers to access genomic information from the most popular ATCC cell lines and primary cell lines and tissues for use in their preclinical experiments without first resorting to lengthy and costly gene sequencing.
The ATCC Cell Line Land database enables researchers to select and order relevant cell lines – cell cultures used to study the effects of compounds in drug development – from ATCC’s biorepository within hours. Cell lines have revolutionized research by replacing primary cells from living tissue, but they do not always replicate accurately. If cell lines are not authenticated by a trusted source like ATCC, they could be contaminated and misidentified. This means researchers usually have to spend weeks or even months sequencing and characterizing cell lines before they can use them for preclinical research.
Unlike existing data repositories, ATCC Cell Line Land provides not only sequencing data on the cell lines, but also detailed information about actual lots of cell lines stored in ATCC’s biorepository, guaranteeing each sample’s intact provenance and its quality as ready-to-use. As a result, researchers can quickly identify and access credible, authenticated and characterized cell lines, which crucially also guarantee reproducible research results. ATCC Cell Line Land also has data on non-cancer cell lines and mouse cell lines, which can’t be found in public sequence data repositories.
“Every dataset we produce contains authenticated data that can be traced to a physical lot of cells in our biorepository,“ said Jonathan Jacobs, Senior Director of Bioinformatics, ATCC. “Having uniformly standardized data production, curation and analysis, we can ensure the highest level of scientific reproducibility ¬– and document and guarantee end-to-end data provenance.”
QDI has proven its ability to provide biopharma with high-quality sequencing data through its OmicSoft Lands databases. These integrate disease-relevant sequencing datasets and their metadata, such as tissue type, biological origin and experimental parameters, from the largest public sequencing dataset repositories. OmicSoft applies controlled vocabularies and skilled manual curation to make these datasets easier to search, compare and explore, making it an ideal framework to also deliver researchers reliable cell line sequence data.
“QDI is proud to have partnered with ATCC to provide access to unique and valuable cell line data to help its customers answer research questions more quickly and efficiently,” said Dr. Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights. “QDI is committed to providing its customers the most comprehensive and manually curated collection of genomic datasets for biopharma researchers to use for biomarker and target discovery and drug development research.”
ATCC Cell Line Land launched on November 1, 2022, featuring 600 of the most commonly used human and mouse cell lines from ATCC’s collection – a further 250 will be added every quarter, including datasets requested by customers. Samples are prepared using ISO-compliant laboratory methods that include QIAGEN RNAeasy technology for RNA purification and ATCC-validated cell culture protocols. Sequence data is processed using standard pipelines to provide comparable datasets.
Every entry in ATCC Cell Line Land is human certified to ensure reliable, high-quality data. After reviewing data submissions, QDI’s expert curators ensure all metadata is absolutely consistent in referencing key characteristics like cell and tissue type, data provenance and cell culture metrics. This quality and accuracy enable the data to be reliably integrated and leveraged with artificial intelligence and machine learning tools.
To learn more about QIAGEN Digital Insights knowledge content, databases and related services and products, please visit https://digitalinsights.qiagen.com/knowledge-and-databases/.
About QIAGEN Digital Insights
QIAGEN Digital Insights, the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools and services for scientists and clinicians. We have over 25 years of experience in the industry, 90,000 users worldwide, over 100,000 citations in scientific papers, more than 3 million profiled patient cases and over 40 billion scientific data points. Discover our portfolio of expertly curated genomic and clinical knowledge solutions as well as bioinformatics software and services for efficient data management, sharing and actionable insights.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2022, QIAGEN employed more than 6,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
About ATCC
ATCC is a premier global biological materials and information resource and standards organization. It is the leading developer and supplier of authenticated cell lines, microorganisms and associated data for academia, industry and government. With its scientific contributions spanning nearly a century, ATCC offers an unmatched combination of the world’s largest and most diverse collection of biological reference materials and data and a trusted, mission-driven partner that believes in scientific collaboration. Its products, services, partnerships and people provide the scientific community with credible, advanced, model systems to support complex research and innovations in basic science, drug discovery, translational medicine and public health. ATCC is a 501(c)3 nonprofit organization with headquarters in Manassas, Virginia, and a research and technology center in Gaithersburg, Maryland. www.atcc.org
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
